专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009076620A1 NANOPARTICULATE ANIDULAFUNGIN COMPOSITIONS AND METHODS FOR MAKING THE SAME 审中-公开
标题翻译：纳米抗菌肽组合物及其制备方法
公开(公告)号：WO2009076620A1
公开(公告)日：2009-06-18
申请号：PCT/US2008/086642
申请日：2008-12-12
申请人： ELAN PHARMA INTERNATIONAL LIMITED , JENKINS, Scott , LIVERSIDGE, Gary , NEVILLE, Debbie
发明人： JENKINS, Scott , LIVERSIDGE, Gary , NEVILLE, Debbie
IPC分类号： A01N25/34 , A61K38/00
CPC分类号： A61K38/12 , A61K9/0019 , A61K9/146
摘要： Nanoparticulate compositions comprising anidulaf ungin are described, as well as methods of making such compositions. Also described are methods for treatment of fungal infections.
摘要翻译：描述了包含anginula ungin的纳米颗粒组合物，以及制备这种组合物的方法。还描述了用于治疗真菌感染的方法。

2. 发明申请

WO2007150075A2 COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE 审中-公开
标题翻译：包含纳米颗粒糊精和受控释放氢化物的组合物
公开(公告)号：WO2007150075A2
公开(公告)日：2007-12-27
申请号：PCT/US2007/072054
申请日：2007-06-25
申请人： ELAN PHARMA INTERNATIONAL LIMITED , STARK, Paul , DEVANE, John , FANNING, Niall , LIVERSIDGE, Gary , JENKINS, Scott , SINGH-REKHI, Gurvinder
发明人： STARK, Paul , DEVANE, John , FANNING, Niall , LIVERSIDGE, Gary , JENKINS, Scott , SINGH-REKHI, Gurvinder
IPC分类号： A61K31/485
CPC分类号： A61K31/485 , A61K9/107 , A61K9/145 , A61K9/146 , A61K9/5026 , A61K9/5078 , A61K9/5084 , A61K9/5138 , A61K9/5161
摘要： The invention relates to a compositions comprising a nanoparticulate meloxicam composition in combination with a multiparticulate modified release hydrocodone composition that, upon administration to a patient, delivers a hydrocodone in a bimodal or multimodal manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component; the first component comprising a first population of hydrocodone - comprising particles and the at least one subsequent component comprising a second population of hydrocodone-comprising particles, wherein the combination of the components exhibit a bimodal or multimodal release profile. The invention also relates to a solid oral dosage form comprising such a combination composition.
摘要翻译：本发明涉及一种组合物，其包含与多颗粒改性释放氢可酮组合物组合的纳米微粒美洛昔康组合物，其在给予患者时以双峰或多峰方式递送氢可酮。多微粒改性组合物包含第一组分和至少一个后续组分; 所述第一组分包含第一群含氢可酮的颗粒，所述至少一个后续组分包含第二组含氢可酮的颗粒，其中所述组分的组合表现出双峰或多峰释放曲线。本发明还涉及包含这种组合组合物的固体口服剂型。

3. 发明申请

WO2007106111A2 NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING NILVADIPINE 审中-公开
标题翻译：包含NILVADIPINE的纳米颗粒和受控释放组合物
公开(公告)号：WO2007106111A2
公开(公告)日：2007-09-20
申请号：PCT/US2006/025803
申请日：2006-06-30
申请人： ELAN PHARMA INTERNATIONAL LIMITED , DEVANE, John , STARK, Paul , FANNING, Niall , REKHI, Gurvinder , JENKINS, Scott , LIVERSIDGE, Gary
发明人： DEVANE, John , STARK, Paul , FANNING, Niall , REKHI, Gurvinder , JENKINS, Scott , LIVERSIDGE, Gary
CPC分类号： A61K9/146 , A61K9/145 , A61K9/1676 , A61K9/2054 , A61K9/5026 , A61K9/5078 , A61K9/5084 , A61K31/44
摘要： The present invention provides a composition comprising nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, useful in the treatment and prevention of hypertension or related cardiovascular disorders. In one embodiment, the composition comprises nanoparticulate particles comprising nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a patient, delivers nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions, and to methods for the treatment and prevention of hypertension or related cardiovascular disorders.
摘要翻译：本发明提供了包含尼伐地平或其盐，衍生物，前药或多晶型物的组合物，其可用于治疗和预防高血压或相关心血管疾病。在一个实施方案中，组合物包含包含尼伐地平或其盐，衍生物，前药或多晶型物和至少一种表面稳定剂的纳米颗粒颗粒。纳米颗粒具有小于约2000nm的有效平均粒度。在另一个实施方案中，组合物包含改性释放组合物，其在给予患者时以双峰，多峰或连续方式递送尼伐地平或其盐，衍生物，前药或多晶型物。本发明还涉及含有这种组合物的剂型，以及治疗和预防高血压或相关心血管疾病的方法。

4. 发明申请

WO2006102117A1 NANOPARTICULATE BIPHOSPHONATE COMPOSITIONS 审中-公开
标题翻译：纳米磷酸二苯酯组合物
公开(公告)号：WO2006102117A1
公开(公告)日：2006-09-28
申请号：PCT/US2006/009791
申请日：2006-03-17
申请人： ELAN PHARMA INTERNATIONAL LIMITED , LIVERSIDGE, Gary , JENKINS, Scott
发明人： LIVERSIDGE, Gary , JENKINS, Scott
IPC分类号： A61K9/51 , A61K9/14 , A61K47/02 , A61P19/08 , A61P9/10 , A61K31/663
CPC分类号： A61K9/146 , A61K9/0019 , A61K9/145 , A61K31/66 , A61K31/663 , Y10S514/824
摘要： Nanoparticulate bisphosphonate compositions, having an effective average particle size of less than 2000 nm, are described. The compositions are useful in treating bone resorption in a mammal.
摘要翻译：描述了具有小于2000nm的有效平均粒度的纳米颗粒二膦酸盐组合物。该组合物可用于治疗哺乳动物的骨吸收。

5. 发明申请

WO2006088864A1 CONTROLLED RELEASE COMPOSITIONS COMPRISING LEVETIRACETAM 审中-公开
标题翻译：包含LEVETIRACETAM的受控释放组合物
公开(公告)号：WO2006088864A1
公开(公告)日：2006-08-24
申请号：PCT/US2006/005167
申请日：2006-02-14
申请人： ELAN PHARMA INTERNATIONAL LIMITED , JENKINS, Scott , LIVERSIDGE, Gary
发明人： JENKINS, Scott , LIVERSIDGE, Gary
IPC分类号： A61K9/22
CPC分类号： A61K9/2077
摘要： The invention relates to a controlled release composition comprising levetiracetam for the treatment of epilepsy. The controlled release composition comprises an immediate release component and a modified release component or formulation. The immediate release component comprises a first population of levetiracetam and the modified release component or formulation preferably comprises a second population of levetiracetam and a controlled release constituent. The modified release formulation is preferably in the form of an erodable formulation, a diffusion controlled formulation or an osmotic controlled formulation. The combination of the immediate release component and the modified release component or formulation in operation deliver the active ingredient in a pulsed or bimodal manner.
摘要翻译：本发明涉及包含用于治疗癫痫的左乙拉西坦的控释组合物。控释组合物包含立即释放组分和改性释放组分或制剂。立即释放组分包含左乙拉西坦的第一群体，并且改性释放组分或制剂优选包含第二群左乙拉西坦和控释组分。改性释放制剂优选为可侵蚀制剂，扩散控制制剂或渗透控制制剂的形式。立即释放组分和操作中的调节释放组分或制剂的组合以脉冲或双峰方式递送活性成分。

6. 发明申请

WO2008030209A3 NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A PLATELET AGGREGATION INHIBITOR 审中-公开
公开(公告)号：WO2008030209A3
公开(公告)日：2008-03-13
申请号：PCT/US2006/019905
申请日：2006-05-23
申请人： ELAN PHARMA INTERNATIONAL LIMITED , LIVERSIDGE, Gary , DEVANE, John , STARK, Paul , FANNING, Niall , REKHI, Gurvinder , JENKINS, Scott
发明人： LIVERSIDGE, Gary , DEVANE, John , STARK, Paul , FANNING, Niall , REKHI, Gurvinder , JENKINS, Scott
IPC分类号： A61K9/20 , A61K31/47 , A01N43/42
摘要： A composition comprising nanoparticulate particles comprising a platelet aggregation inhibitor, for example, cilostazol, or a salt or derivative thereof, useful in the treatment and prevention of ischemic symptoms, and at least one surface stabilizer is disclosed. The nanoparticles have an effective average size of less than about 2000 nm. The composition delivers the platelet aggregation inhibitor, or nanoparticles comprising the same in a pulsatile or continuous manner.

7. 发明申请

WO2007150074A3 COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE HYDROCODONE 审中-公开
公开(公告)号：WO2007150074A3
公开(公告)日：2007-12-27
申请号：PCT/US2007/072052
申请日：2007-06-25
申请人： ELAN PHARMA INTERNATIONAL LIMITED , STARK, Paul , DEVANE, John , FANNING, Niall , LIVERSIDGE, Gary , JENKINS, Scott , SINGH-REKHI, Gurvinder
发明人： STARK, Paul , DEVANE, John , FANNING, Niall , LIVERSIDGE, Gary , JENKINS, Scott , SINGH-REKHI, Gurvinder
IPC分类号： A61K31/4375 , A61K31/12 , A61K9/22
摘要： The invention relates to a compositions comprising a nanoparticulate naproxen composition in combination with a multiparticulate modified release hydrocodone composition that, upon administration to a patient, delivers a hydrocodone in a bimodal or multimodal manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component; the first component comprising a first population of hydrocodone - comprising particles and the at least one subsequent component comprising a second population of hydrocodone-comprising particles, wherein the combination of the components exhibit a bimodal or multimodal release profile. The invention also relates to a solid oral dosage form comprising such a combination composition.

8. 发明申请

WO2007027273A1 NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS 审中-公开
标题翻译：包含芳基 - 杂环化合物的纳米颗粒和控制释放组合物
公开(公告)号：WO2007027273A1
公开(公告)日：2007-03-08
申请号：PCT/US2006/023695
申请日：2006-06-19
申请人： ELAN PHARMA INTERNATIONAL LIMITED , DEVANE, John , STARK, Paul , FANNING, Niall , REKHI, Gurvinder , JENKINS, Scott , LIVERSIDGE, Gary
发明人： DEVANE, John , STARK, Paul , FANNING, Niall , REKHI, Gurvinder , JENKINS, Scott , LIVERSIDGE, Gary
IPC分类号： A61K9/64
CPC分类号： A61K9/5078 , A61K9/145 , A61K9/146 , A61K9/4808 , A61K9/5084
摘要： The present invention provides a composition comprising ziprasidone useful in the treatment and prevention of schizophrenia and similar psychiatric disorders. In one embodiment, the composition comprises nanoparticulate particles comprising ziprasidone and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a patient, delivers ziprasidone in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions, and to methods for the treatment and prevention of schizophrenia and similar psychiatric disorders.
摘要翻译：本发明提供一种包含齐拉西酮的组合物，其可用于治疗和预防精神分裂症和类似的精神障碍。在一个实施方案中，组合物包含包含齐拉西酮和至少一种表面稳定剂的纳米颗粒颗粒。纳米颗粒具有小于约2000nm的有效平均粒度。在另一个实施方案中，组合物包含改性释放组合物，其在给予患者时以双峰，多峰或连续方式递送齐拉西酮。本发明还涉及含有这些组合物的剂型，以及治疗和预防精神分裂症和类似精神障碍的方法。

9. 发明申请

WO2007008537A3 NANOPARTICULATE CLARITHROMYCIN FORMULATIONS 审中-公开
公开(公告)号：WO2007008537A3
公开(公告)日：2007-01-18
申请号：PCT/US2006/026232
申请日：2006-07-06
申请人： ELAN PHARMA INTERNATIONAL, LIMITED , JENKINS, Scott , LIVERSIDGE, Gary
发明人： JENKINS, Scott , LIVERSIDGE, Gary
IPC分类号： A61K9/51 , A61K9/14
摘要： The present invention is directed to compositions comprising nanoparticulate macrolides such as clarithromycin, or a salt or derivative thereof, having improved bioavailability. The nanoparticulate macrolide particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of infection and related diseases.

10. 发明申请

WO2006096462A1 NANOPARTICULATE COMPOSITIONS OF HETEROCYCLIC AMIDE DERIVATIVES 审中-公开
标题翻译：杂环化合物衍生物的纳米颗粒组合物
公开(公告)号：WO2006096462A1
公开(公告)日：2006-09-14
申请号：PCT/US2006/007465
申请日：2006-03-02
申请人： ELAN PHARMA INTERNATIONAL LIMITED , LIVERSIDGE, Gary , JENKINS, Scott
发明人： LIVERSIDGE, Gary , JENKINS, Scott
IPC分类号： A61K9/14
CPC分类号： A61K9/145 , A61K9/146 , A61K9/2018 , A61K9/2027 , A61K9/205 , A61K9/2054 , A61K9/2077
摘要： The present invention is directed to compositions comprising nanoparticulate heterocyclic amide derivative and preferably zafirlukast nanoparticles, also collectively referred to as "active ingredient," having improved solubility in water. The nanoparticles of the composition have an effective average particle size of less than about 2,000 nm, and are useful in the treatment of asthma. The invention also relates to a multiparticulate modified release composition comprising the active ingredient that in operation delivers the drug in a pulsed or bimodal manner for the treatment of asthma. The controlled release composition comprises an immediate release component and a modified release component. The immediate release component comprises a first population of heterocyclic amide derivative, and preferably zafirlukast particles, and the modified release component comprises a second population of heterocyclic amide derivative, and preferably zafirlukast nanoparticles, and a controlled release component, wherein the combination of the immediate release and modified release components in operation delivers the active ingredient in a pulsed or bimodal manner. The heterocyclic amide derivative can be released from the multiparticulate particles in an erosable, diffusion or osmotic controlled release system.
摘要翻译：本发明涉及包含纳米颗粒杂环酰胺衍生物和优选扎非司酮纳米颗粒的组合物，其也统称为“活性成分”，其具有改善的在水中的溶解度。组合物的纳米颗粒具有小于约2,000nm的有效平均粒度，并且可用于治疗哮喘。本发明还涉及一种多微粒改性释放组合物，其包含在操作中以脉冲或双峰方式递送药物以治疗哮喘的活性成分。控释组合物包含立即释放组分和改性释放组分。立即释放组分包含第一批杂环酰胺衍生物，优选扎法司他颗粒，并且改性释放组分包含第二组杂环酰胺衍生物，优选扎非司酮纳米颗粒和控释组分，其中立即释放组合并且操作中的改性释放组分以脉冲或双峰方式递送活性成分。杂环酰胺衍生物可以在可侵蚀，扩散或渗透控制释放系统中从多颗粒颗粒中释放。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式